From Data Access to Data Readiness

The Next Bottleneck in AI-Driven Small Molecule Discovery

AI Is Advancing Rapidly in Drug Discovery — But Is Your Data Ready?

Join leading experts from AI-first biotech, computational chemistry, and pharmaceutical R&D as they discuss how transforming fragmented scientific data into AI-ready intelligence is accelerating modern small molecule discovery workflows.

Why AI-Driven Small Molecule Discovery Needs Better Data

AI models today can generate predictions faster than ever before — but without standardized, context-rich, and integrated datasets, even the most advanced systems struggle to deliver reliable outcomes.

This exclusive panel discussion hosted on the Pistoia Alliance platform will explore why data readiness — not compute power — has become the true bottleneck in scaling AI-driven drug discovery.

Key Takeaways

• Why data readiness is becoming the biggest bottleneck in AI-driven drug discovery
• How leading biotech and pharma teams are overcoming fragmented scientific data challenges
• What it takes to build scalable, AI-ready discovery workflows and datasets

Speakers

• Saro Passaro, Co-Founder Boltz PBC
• Daniel Price, VP , Computational Chemistry, Nimbus Therapeutics
• Dr. Govinda Bhisetti, Former VP & Head of Computational Chemistry, Cellarity

Moderators

• Vladimir Makarov, Project Manager, Pistoia Alliance
• Norman Azoulay, Vice President of Product, Platforms and Data, Excelra